Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Abstract: Two samples harbored the T215S, M184V and K70E mutations related to nucleoside RTIs (NRTIs).
Result: In one participant, two NRTIs-resistance mutations (M184V, K70E) were observed.
Result: The M184V mutation can contribute to resistance if present along with other major resistance mutations high level resistance to lamivudine (3TC) and emtricitabine, and low-level resistance to didanosine and abacavir.
Table: M184V
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
PMID: 33649107
2021
Antimicrobial agents and chemotherapy
Introduction: Likewise, cases of failure with emergent M184V and R263K were reported for DTG-plus-lamivudine dual therapy in the clinical trials GEMINI and ACTG5353.
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Abstract: M184I/V (emtricitabine RAM) was detected in one patient in each arm of AMBER.
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Result: Besides DRMs assessed by PANDAA (K65R, M184V, K103N, Y181C and G190A), additional major DRMs to NRTI (L74I, D67N, K70E and K219R) were found in 3/120 participants (3%), as follows: L74I in combination with M184V were found in 2/120 participants (2%) and D67N +K70E+219R together with M184V occurred in 1 participant (1%).
Result: Pre-treatment drug resistance (K65R, M184V,
Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Cote d'Ivoire.
Abstract: Frequently encountered resistance mutations were for NRTIs: M184V (88%), TAMs (67%), T215F/I/V/Y (33%), and L74I/V (24%); for NNRTIs: K103N/S (74%), P225H (26%), and G190A/E/Q (24%).
Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
PMID: 33196554
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: MT-2 cells were infected with wild-type or low frequency M184V HIV-1, exposed to drug combinations, monitored for VB, and rebound virus was deep sequenced.
Abstract: RESULTS: Cultures infected with wild-type or low frequency M184V HIV-1 showed no VB with BIC+FTC+TAF at drug concentrations corresponding to Cmin, Cmin - 1, or Cmin - 2 but breakthrough did occur in 26 of 36 cultures at Cmin - 3, where the M184V variant emerged in one culture.
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PMID: 33200210
2021
The Journal of antimicrobial chemotherapy
Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.
First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname.
PMID: 33287618
2021
AIDS research and human retroviruses
Abstract: The most common DRMs were M184V (23.6%) and K103N (18.8%).
"Detection of Drug Resistance Mutations in the Reverse Transcriptase Gene of HIV-1-Infected North Indian Population Failing First-Line Antiretroviral Therapy ""A Follow-Up Cohort Study""."
PMID: 33390085
2021
AIDS research and human retroviruses
Abstract: Drug resistance mutation M184V (ATG to GTA) (63.15%) associated with lamivudine and abacavir and K103N (AAG or AAA to AAU) (36.84%) associated with efavirenz and nevirapine were predominantly identified in first-line ART failure patients.
HIV mutation literature information.
PMID: 
2021
Drug design, development and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT